Phospho-specific flow cytometry: intersection of immunology and biochemistry at the single-cell level.

Stanford University, Department of Microbiology and Immunology, Baxter Laboratory of Genetic Pharmacology, 269 Campus Drive, Stanford, CA 94305, USA.
Current opinion in molecular therapeutics (Impact Factor: 3.42). 07/2006; 8(3):215-24.
Source: PubMed

ABSTRACT Striving to achieve greater clinical relevance, researchers in basic science and in drug discovery are transitioning from biochemical investigations using cell lines to technologies that garner mechanistic information from primary patient material. Such studies can be broad in scope, despite limited sample material and cell-type heterogeneity. The development of flow cytometry for following intracellular signaling has met some of these demands and opened new avenues for mechanistic exploration. This review covers some of the most recent research to leverage this new technology and follows two new developments: increasing interest in JAK/STAT signaling, and experimental strategies that reveal disease-induced modulation of signaling networks.

  • [Show abstract] [Hide abstract]
    ABSTRACT: A clinically useful tool to assay phosphorylation-dependent signaling in circulating cells has the potential to provide a wealth of information about a patient's health, including information unavailable by any other method. Patterns of kinase activation, such as the abnormal signaling characteristic of myeloproliferative disorders, may offer highly specific biomarkers for diagnosis or monitoring the efficacy of therapeutics. For assays of kinase activity in circulating leukocytes to be standardized, let alone made practical for the clinic, numerous technical hurdles must be overcome. In this review the current status of analysis of kinase signaling in circulating cells and recent progress in biomarker discovery and validation is discussed. Looking forward, the potential value of signaling patterns as complex biomarkers and the resulting need for future development of robust, multiplexed assays of kinase activation is addressed.
    Expert Opinion on Medical Diagnostics 01/2008; 2(1):33-46.
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: There is a need in prostate cancer diagnostics and research for a label-free imaging methodology that is nondestructive, rapid, objective, and uninfluenced by water. Raman spectroscopy provides a molecular signature, which can be scaled from micron-level regions of interest in cells to macroscopic areas of tissue. It can be used for applications ranging from in vivo or in vitro diagnostics to basic science laboratory testing. This work describes the fundamentals of Raman spectroscopy and complementary techniques including surface enhanced Raman scattering, resonance Raman spectroscopy, coherent anti-Stokes Raman spectroscopy, confocal Raman spectroscopy, stimulated Raman scattering, and spatially offset Raman spectroscopy. Clinical applications of Raman spectroscopy to prostate cancer will be discussed, including screening, biopsy, margin assessment, and monitoring of treatment efficacy. Laboratory applications including cell identification, culture monitoring, therapeutics development, and live imaging of cellular processes are discussed. Potential future avenues of research are described, with emphasis on multiplexing Raman spectroscopy with other modalities.
    CANCER AND METASTASIS REVIEW 02/2014; · 9.35 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Advanced single cell analysis technologies (e.g. Mass Cytometry) that help in multiplexing cellular measurements in limited volumes of primary cells are critical in bridging the discovery efforts to successful drug approval. Mass cytometry is the state-of-the-art technology in multi-parametric single-cell analysis. Mass cytometers (also known as CyTOF or Cytometry by Time-of-Flight) combine the cellular analysis principles of traditional fluorescence-based flow cytometry with the selectivity and quantitative power of Inductively Coupled Plasma-Mass Spectrometry (ICP-MS). Standard flow cytometry is limited in the number of parameters that can be measured due to the overlap in signal when detecting the fluorescently labeled antibodies. Mass cytometry uses antibodies tagged to stable isotopes of rare earth metals, requiring minimal signal compensation between the different metal tags. This unique feature enables researchers to seamlessly multiplex up to 40 independent measurements on single cells. In this perspective we first present an overview of mass cytometry and compare it with traditional flow cytometry. We then discuss emerging and potential applications of CyTOF technology in the pharmaceutical industry that include quantitative and qualititative deep profiling of immune cells and their use application in assessing drug immunogenicity, extensive mapping of signaling networks in single cells, cell surface receptor quantification and multiplexed internalization kinetics, multiplexing sample analysis by barcoding, and establishing cell ontologies based on phenotype and/or function. We end with a discussion on the anticipated impact of this technology on drug development lifecycle with special emphasis on the utility of mass cytometry in deciphering the drug's pharmacokinetics and pharmacodynamics relationship.
    Drug metabolism and disposition: the biological fate of chemicals 10/2014; · 3.74 Impact Factor